Search research articles
Contact Us
Filters
Showing results (791-800 of 921) with videos related to
Page
of 93
Sort By:
Leukemia
|
January 12, 2013
The viral oncogene Np9 acts as a critical molecular switch for co-activating β-catenin, ERK, Akt and Notch1 and promoting the growth of human leukemia stem/progenitor cells
T Chen, Z Meng, Y Gan, et al.
British Journal of Cancer
|
January 20, 2017
A phase III randomised controlled trial of erlotinib vs gefitinib in advanced non-small cell lung cancer with EGFR mutations
J J Yang, Q Zhou, H H Yan, et al.
Lancet (London, England)
|
September 30, 2018
Measuring human capital: a systematic analysis of 195 countries and territories, 1990-2016
Stephen S Lim, Rachel L Updike, Alexander S Kaldjian, et al.
NMR in Biomedicine
|
November 22, 2023
Uncovering prostate cancer aggressiveness signal in T2-weighted MRI through a three-reference tissues normalization technique
Ahmad Algohary, Evangelia I Zacharaki, Adrian L Breto, et al.
Zhonghua Yi Xue Za Zhi
|
July 15, 2025
[Predictive value of CT-based tumor and peritumoral radiomics for WHO/ISUP grading of non-metastatic clear cell renal cell carcinoma]
J K Xu, H Guo, Z Y Wang, et al.
Cancers
|
November 14, 2023
Clinical-Genomic Risk Group Classification of Suspicious Lesions on Prostate Multiparametric-MRI
Radka Stoyanova, Olmo Zavala-Romero, Deukwoo Kwon, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
October 5, 2014
Pemetrexed versus gefitinib as a second-line treatment in advanced nonsquamous nonsmall-cell lung cancer patients harboring wild-type EGFR (CTONG0806): a multicenter randomized trial
Q Zhou, Y Cheng, J-J Yang, et al.
ERJ Open Research
|
September 25, 2024
AERIFY-1/2: two phase 3, randomised, controlled trials of itepekimab in former smokers with moderate-to-severe COPD
Klaus F Rabe, Fernando J Martinez, Surya P Bhatt, et al.
The American Journal of Pathology
|
October 31, 2024
Programmed Death Ligand-1 in Melanoma and Extracellular Vesicles Promotes Local and Regional Immune Suppression through M2-like Macrophage Polarization
Lili Huang, Jingbo Yang, Jinjin Zhu, et al.
ESMO Open
|
May 28, 2025
Health-related quality of life analysis of the LEAP-002 study of lenvatinib plus pembrolizumab versus lenvatinib as first-line treatment for advanced hepatocellular carcinoma
R S Finn, M Kudo, P Merle, et al.
Page
of 93
Search research articles
Search
Showing results (791-800 of 921) with videos related to
Sort By:
Page
of 93
Leukemia
|
January 12, 2013
The viral oncogene Np9 acts as a critical molecular switch for co-activating β-catenin, ERK, Akt and Notch1 and promoting the growth of human leukemia stem/progenitor cells
T Chen, Z Meng, Y Gan, et al.
British Journal of Cancer
|
January 20, 2017
A phase III randomised controlled trial of erlotinib vs gefitinib in advanced non-small cell lung cancer with EGFR mutations
J J Yang, Q Zhou, H H Yan, et al.
Lancet (London, England)
|
September 30, 2018
Measuring human capital: a systematic analysis of 195 countries and territories, 1990-2016
Stephen S Lim, Rachel L Updike, Alexander S Kaldjian, et al.
NMR in Biomedicine
|
November 22, 2023
Uncovering prostate cancer aggressiveness signal in T2-weighted MRI through a three-reference tissues normalization technique
Ahmad Algohary, Evangelia I Zacharaki, Adrian L Breto, et al.
Zhonghua Yi Xue Za Zhi
|
July 15, 2025
[Predictive value of CT-based tumor and peritumoral radiomics for WHO/ISUP grading of non-metastatic clear cell renal cell carcinoma]
J K Xu, H Guo, Z Y Wang, et al.
Cancers
|
November 14, 2023
Clinical-Genomic Risk Group Classification of Suspicious Lesions on Prostate Multiparametric-MRI
Radka Stoyanova, Olmo Zavala-Romero, Deukwoo Kwon, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
October 5, 2014
Pemetrexed versus gefitinib as a second-line treatment in advanced nonsquamous nonsmall-cell lung cancer patients harboring wild-type EGFR (CTONG0806): a multicenter randomized trial
Q Zhou, Y Cheng, J-J Yang, et al.
ERJ Open Research
|
September 25, 2024
AERIFY-1/2: two phase 3, randomised, controlled trials of itepekimab in former smokers with moderate-to-severe COPD
Klaus F Rabe, Fernando J Martinez, Surya P Bhatt, et al.
The American Journal of Pathology
|
October 31, 2024
Programmed Death Ligand-1 in Melanoma and Extracellular Vesicles Promotes Local and Regional Immune Suppression through M2-like Macrophage Polarization
Lili Huang, Jingbo Yang, Jinjin Zhu, et al.
ESMO Open
|
May 28, 2025
Health-related quality of life analysis of the LEAP-002 study of lenvatinib plus pembrolizumab versus lenvatinib as first-line treatment for advanced hepatocellular carcinoma
R S Finn, M Kudo, P Merle, et al.
Page
of 93